explore -WSS

explore

author：hotspot 2025-09-06 02:10:21 - browse：97

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Intellia plays down concerns on accidental germline transmission

WSS

Wegovy improves function in certain heart failure patients

DeSantis wants to import drugs. Biden’s FDA blasted his plan

PBMs are inflating the cost of generic drugs. They must be reined in

Medicare has a new plan to address drug shortages

FDA approves RSV monoclonal antibody for infants, toddlers

At Orexo, a ‘turning point’ for everything but digital health

leisure time

explore

explore

Novavax promises a turnaround & Lilly roils the obesity market

People can get long Covid without testing positive for virus: Study

Jerome Adams on the need for new antivirals for Covid

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Duchenne breakthrough therapy leaves behind pioneering families

People can get long Covid without testing positive for virus: Study

As demand for Covid shots wanes, Moderna seeks its next success

Study: Spinal cord stimulation helps patients with paralysis walk again

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Virtual Event: The State of Biosimilars: What to Watch

hotspot

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Startup Neumora takes a novel depression drug to Phase 3

California store owner shot dead in dispute over displaying Pride flag: Police

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

National associations that represent hospice owe an apology

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Wikipedia

focus

hotspot

focus